Trandolapril and verapamil SR combination effectiveness in arterial hypertension patients

Abstract

Aim. To study the effects of fixed4dose combined trandolapril and verapamil SR (Tarka) therapy on blood pressure (BP) and renin-angiotensin-aldosterone system (RAAS) patients with in essential arterial hypertension (EAH) and renal AH. Material and methods. The study included 20 patients with mild to moderate AH; 16 completed the study. EAH was diagnosed in 9 participants, secondary AH and chronic pyelonephritis – in 7. At baseline and 8 weeks later, office BP measurement, 24-hour BP monitoring (BPM), vectorcardiography and decartography parameters, renin activity (RA), aldosterone, potassium, microalbuminuria (MAU) level measurement were performed. Results. Target systolic BP (SBP) levels, <140 mm Hg, were achieved in 93,7%, and target diastolic BP (DBP) levels, <90 mm Hg – in 62,5% of the cases. Total target BP level achievement rate was 62,5%. According to 24-hour BPM data, positive day and nighttime SBP and DBP dynamics was observed. Mean MAU reduced significantly, from 27,6±23,9 mg/d to 17,2±14,5 mg/d. RASS status improved, as the number of patients with initially decreased RA halved. Conclusion. Antihypertensive effectiveness was demonstrated for Tarka medication in patients with mild to moderate AH. Its effectiveness was similar in participants with EAH and renal AH. Positive MAU dynamics confirms Tarka nephroprotective action.

Keywords

• trandolapril and verapamil sr combination (tarka)
• arterial hypertension
• microalbuminuria